1. Home
  2. CRSP vs GNTX Comparison

CRSP vs GNTX Comparison

Compare CRSP & GNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

HOLD

Current Price

$56.49

Market Cap

5.1B

Sector

Health Care

ML Signal

HOLD

Logo Gentex Corporation

GNTX

Gentex Corporation

HOLD

Current Price

$24.02

Market Cap

5.2B

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRSP
GNTX
Founded
2013
1974
Country
Switzerland
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Auto Parts:O.E.M.
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
5.1B
5.2B
IPO Year
2016
N/A

Fundamental Metrics

Financial Performance
Metric
CRSP
GNTX
Price
$56.49
$24.02
Analyst Decision
Buy
Buy
Analyst Count
19
6
Target Price
$71.50
$29.00
AVG Volume (30 Days)
1.7M
1.9M
Earning Date
02-10-2026
01-30-2026
Dividend Yield
N/A
1.98%
EPS Growth
N/A
N/A
EPS
N/A
1.70
Revenue
$38,337,000.00
$2,431,504,922.00
Revenue This Year
N/A
$11.92
Revenue Next Year
$718.51
$4.98
P/E Ratio
N/A
$14.31
Revenue Growth
N/A
3.00
52 Week Low
$30.04
$20.28
52 Week High
$78.48
$29.38

Technical Indicators

Market Signals
Indicator
CRSP
GNTX
Relative Strength Index (RSI) 51.43 53.21
Support Level $53.37 $24.00
Resistance Level $60.73 $24.92
Average True Range (ATR) 2.33 0.45
MACD 0.12 0.07
Stochastic Oscillator 47.39 51.87

Price Performance

Historical Comparison
CRSP
GNTX

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

About GNTX Gentex Corporation

Gentex was founded in 1974 to produce smoke-detection equipment. The company sold its first glare-control interior mirror in 1982 and its first model using electrochromic technology in 1987. Automotive revenue is about 98% of total revenue. The company is constantly developing new applications for the technology to remain on top. Sales in 2024 totaled about $2.3 billion with 47.7 million mirrors shipped. The unit mix breaks out as 63% interior and 37% exterior, versus 31% exterior in 2019. The company is based in Zeeland, Michigan.

Share on Social Networks: